Delgocitinib: First Approval

@article{Dhillon2020DelgocitinibFA,
  title={Delgocitinib: First Approval},
  author={Sohita Dhillon},
  journal={Drugs},
  year={2020},
  volume={80},
  pages={609-615}
}
Delgocitinib, a janus kinase (JAK) inhibitor, is being developed by Japan Tobacco for the treatment of autoimmune disorders and hypersensitivity, including inflammatory skin conditions. The JAK family of tyrosine kinases plays an important role in mediating the biological effects of several inflammatory cytokines, e.g. IL-4, IL-13 and IL-31, which are elevated in patients with atopic dermatitis. Delgocitinib inhibits all members of the JAK family [JAK1, JAK2, JAK3 and tyrosine kinase 2… 
Safety of Janus kinase (JAK) inhibitors in the short-term treatment of atopic dermatitis.
TLDR
The most prevalent treatment-emergent adverse events from oral JAK inhibitor use in AD were nausea, upper respiratory tract infection, headache, herpes zoster, herpes simplex, acne, increased blood creatine phosphokinase levels, and decreased platelet counts.
Emerging Role of Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis
TLDR
Short-term data suggest that both topical and oral JAK inhibitors are efficacious and safe for use in patients with AD, although cases of thrombosis and viral disease have been reported.
Jakinibs of All Trades: Inhibiting Cytokine Signaling in Immune-Mediated Pathologies
TLDR
Jakinibs that are approved or are under late phase investigation are reviewed, focusing on clinical applications, pharmacokinetic and safety profiles, and future opportunities and challenges.
Evaluating topical JAK inhibitors as a treatment option for atopic dermatitis
TLDR
Although topical JAK inhibitors have promising efficacy and safety profiles, poor medication adherence common to topical treatments may limit their utility in a clinical setting.
Ruxolitinib Cream Has Dual Efficacy on Pruritus and Inflammation in Experimental Dermatitis
TLDR
Ruxolitinib cream was highly effective at ameliorating disease symptoms in multiple murine dermatitis models through downregulation of T helper (Th)2-driven inflammation, resulting in reduced skin thickening and decreased itch.
JAK3 inhibitors for the treatment of inflammatory and autoimmune diseases: a patent review (2016–present)
TLDR
A comprehensive review of the available patent literature on JAK-family inhibitors published from 2016 to the present found that selective JAK3 inhibitors may offer valid, interesting, and promising therapeutic potential in inflammatory and autoimmune diseases.
JAK inhibitors in the treatment of atopic dermatitis
The inhibition of the Janus kinase (JAK)–signal transducers and activators of transcription pathway, a recently discovered pathway, has been shown to treat patients with atopic dermatitis. All four
Atopic dermatitis: an expanding therapeutic pipeline for a complex disease
  • T. Bieber
  • Biology, Medicine
    Nature reviews. Drug discovery
  • 2021
TLDR
This Review assesses the various strategies and novel agents currently being investigated for AD and highlights the potential for a precision medicine approach to enable prevention and more effective long-term control of this complex disease.
...
1
2
3
4
...

References

SHOWING 1-10 OF 20 REFERENCES
Long‐term safety and efficacy of delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with atopic dermatitis
TLDR
Delgocitinib 0.5% ointment was well tolerated and effective when administrated to Japanese adult patients with AD for up to 52 weeks, and the improvement effects on AD as assessed by mEASI were maintained throughout the treatment period.
A novel JAK inhibitor JTE‐052 reduces skin inflammation and ameliorates chronic dermatitis in rodent models: Comparison with conventional therapeutic agents
TLDR
The results indicate that JTE‐052 is a promising candidate as an anti‐inflammatory drug for various types of chronic dermatitis, with a distinctly different profile from conventional therapy following either oral or topical application.
Clinical Practice Guidelines for the Management of Atopic Dermatitis 2016
TLDR
The guidelines present recommendations to review clinical research articles, evaluate the balance between the advantages and disadvantages of medical activities, and optimize medical activity‐related patient outcomes with respect to several important points requiring decision‐making in clinical practice.
Phase 1 studies to assess the safety, tolerability and pharmacokinetics of JTE‐052 (a novel Janus kinase inhibitor) ointment in Japanese healthy volunteers and patients with atopic dermatitis
TLDR
The results suggest that the treatment of JTE‐052 ointment is generally safe and effective in AD patients, although further large confirmatory studies are needed.
Pharmacological properties of JTE-052: a novel potent JAK inhibitor that suppresses various inflammatory responses in vitro and in vivo
TLDR
The present results indicate that JTE-052 is a highly potent JAK inhibitor, and represents a candidate anti-inflammatory agent for suppressing various types of inflammation.
Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis.
...
1
2
...